Therapeutical Class：Fluoroquinolones, inhibition of DNA gyrase and prevention of DNA replication

Indication：Urinary tract infections including pyelonephritis, chroic bacteria prostatitis, chronic bronchitis, community-acquired pneumonia (including penicillin-resistant S. pneumoniae), skin and soft tissue infections, and maxillary sinusitis.

Administraton：PO, IV.

Adults: 250-500 mg qd;

Severe or complicated infections: 750 mg qd.

Tuberculosis treatment (second-line): 500-1000 mg/day in combination with other antitubercular antibiotics.

Renal impairment:

Intial dose 750 mg: Ccr 20-49 ml/min, 750 mg qod; Ccr 10-19 ml/min,

HD, CAPD, 500 mg qod.

Intial dose 500 mg: Ccr 20-49 ml/min, 250 mg qd; Ccr 10-19 ml/min,

HD, CAPD, 250 mg qod.

Intial dose 250 mg: Ccr 10-19 ml/min, 250 mg qod.

Adverse Effect：Nausea, headache (1-10%), diarrhea (1-10%), insomnia, allergy (rash,etc.) (1-10%), dizziness, constipation, seizures, QT prolongation, tendinitis (<1%), photosensitization (<1%).

Contraindication：Hypersensitivity to other quinolones, concurrent use of dronedarone, ziprasidone.

Pregnancy Risk：C

Supply：Cravit XE “Cravit” Tab 500mg（可樂必妥錠 第一三共）＜10694＞

Cravit XE “Cravit” IV Soln 5mg/ml 100ml/vl（可樂必妥輸注液 第一三共）＜10983＞